CN104224817B - Application of panaxadiol saponin component in preparing antischizophrenic drug - Google Patents

Abstract

The invention provides an application of a panaxadiol saponin component in preparing an antischizophrenic drug. The application comprises treatment of schizophrenia and resistance of toxic side effect, namely an extrapyramidal symptom and the like which are caused by the antischizophrenic drug, wherein the antischizophrenic drug comprises the panaxadiol saponin component independently or with other medicines and other active compounds and pharmaceutically acceptable carriers. The invention proves that the panaxadiol saponin component (Rb) can improve the cognitive ability of a schizophrenia animal model, resist the nerve toxic side effect of multiple schizophrenia drugs, improve the negative symptoms (such as cognition impairment) of the schizophrenia and is applied to preparing the antischizophrenic drug.

Description

The antipsychotic medical usage of PDS component

Technical field

The invention belongs to field of medicaments, is related to PDS active component（Abbreviation Rb below) preparing the spiritual disease of preventing and treating Application in medicine.More specifically, individually or with other materials known anti-spirit is included using PDS component Division disease drug be particularly chlorpromazine, haloperole, Clozapine together made by pharmaceutical preparation treatment mental illness medicine should With the separately made pharmaceutical preparation of PDS component is used in combination with existing antipsychotic drug and plays synergistic effect and subtract Toxic action.

Background technology

Existing antipsychotics has many defects, needs safer, significantly more efficient medicine.

With the quickening of social rhythm, people face from each side pressure spirit aspect be chronically at inferior health shape State, develops in the course of time mental illness, and such as not in time treatment will have a strong impact on the productive life activity even harm of people Life.Schizophrenia is mental disease, the clinical syndrome being made up of one group of syndrome, and it is multifactorial disease. Although still not bery clear and definite to the understanding of its cause of disease at present, the undesirable element of the susceptible quality of individual mind and outside social environment Effect to the generation development of disease is known together by everybody.Either susceptible quality or outside undesirable element all may pass through Inherent biological factor collective effect and cause the generation of disease, different patients its morbidity factor may be with a certain respect more It is important.Schizoid clinical symptoms complexity is various, can relate to sensory perception, thinking, emotion, act of will and cognitive function etc. Aspect, symptom is widely different between individuality, even if same patient is likely to show different symptoms in different phase or stadium.

Anti- schizophrenia medicine is to schizoid positive symptom（Including disturbance in thinking, vain hope, illusion, dyskinesia Deng）Therapeutic effect is preferable, but to negative symptoms（Consciousness slow in reacting, shortage interest blank etc. and cognitive impairment, notice Decline, memory disorders perform function obstacle etc.）Invalid or effectiveness is low and can damage the cognitive function of patient.From first anti-spirit Sick medicine（Chlorpromazine）Since being applied to clinic, through the struggle of decades, nowadays anti-schizophrenia medicine there has been the third generation, not only There is good curative effect to positive symptom while its negative symptoms can also be improved.But six during the last ten years, we still cannot gram Take numerous shortcomings of anti-schizophrenia medicine（In the extrapyramidal symptoms, muscular rigidity, cognition dysfunction, metabolic syndrome, nerve Dyssecretosis etc.）, and anti-schizophrenia medicine needs long-term taking to have a strong impact on the social activities of patient, Most patients because Its a series of side reaction cannot be stood and be voluntarily discontinued and caused aggravation.

Chlorpromazine（Chlorpromazine, CHL）Have great importance as first anti-schizophrenia medicine, it is opened By mental illness and the intracerebral chemical substance unbalance new page for connecting, up to the present chlorpromazine is by working for the mankind Hurry up, cheap, drug effect substantially etc. advantage still in wide clinical application, but its many side reactions such as the extrapyramidal symptoms, Muscular rigidity etc. is that he cannot overcome itself with the toxic and side effect of drug effect, so far there is not yet having for its toxic and side effect can be mitigated Efficacious prescriptions method.

Haloperole（Haloperidol, HAL）A kind of anti-schizophrenia medicine of typical butyrophenones, its pharmacological action with The anti-schizophrenia medicine of phenothiazines is similar to, it may also be used for the acute think of for the treatment of feels imbalance and wildly arrogant disease.Action principle is with chlorpromazine phase All it is seemingly dopamine receptor-blocking agent.Same its more serious the extrapyramidal symptoms, only just can be controlled when dosage is reduced System, but drug effect can be reduced again when dosage is reduced.

Clozapine（Clozapine, CLO）It is the Typical Representative of the anti-schizophrenia medicine of the second generation, not only to psychosis positive Symptom effectively, also has certain effect to negative symptoms.It is absurd to illusion suitable for acute and chronic schizophrenia each hypotype Think that type, hebephrenictype effect are good.The affective symptom relevant with schizophrenia can also be mitigated（Such as：Depression, sense of guilt, anxiety）. Some are failed to respond to any medical treatment with traditional antipsychotics or patient that curative effect is bad, using Clozapine instead may be effectively.The medicine is also used for The excited restless and illusion vain hope for the treatment of mania or other psychotic disorders.It is general unsuitable because causing agranulocytosis As choice drug；Sedation is strong and anticholinergic bad reaction is more, it is common have dizzy, powerless, drowsiness, hidrosis, salivation, Nausea and vomiting, dry, constipation, postural hypotension, tachycardia；Common appetite increases and increased weight；Electrocardiogram can be caused Abnormal change, can cause electroencephalogram to change or schizophrenia outbreak.

Yet there are no a certain medicine in world wide at present can reduce the side reaction of said medicine, and combine other drugs More serious side reaction and some other more serious reaction often occurs, such as levodopa is used in combination with phenothiazines medicine When, the latter can suppress the former Antiparkinsonian effect；Haloperole is shared with ethyldopa, can produce the disturbance of consciousness, thinking Slow, disorientation etc.；Clozapine is shared with macrolide antibiotics can be such that plasma clozapine significantly raises, and have report Road induction schizophrenia outbreak.The present invention relates to application of the PDS component in treatment schizophrenia, exactly will A kind of and other anti-schizophrenia Drug combinations are provided, both can greatly strengthen the anti-spirit of existing anti-schizophrenia medicine Division curative effect can reduce the medicine of their toxic and side effect again, so as to overcome anti-schizophrenia curative effect of medication at present not enough and safe The low defect of property.

Panoxadiol type saponin(e and three alcohol type saponin(es are used in mixed way the clinical treatment effect that can interfere ginseng or American Ginseng Really.

Ginseng and American Ginseng are rare Chinese medicine, and the property of medicine of the two, effect and clinical application are then significantly different, it is this not It is both different by their principle active component and determines.The ginseng property of medicine is warmed, and is temperature compensation medicine, with reinforcing vital energy, is taken off admittedly, The effects such as returning sun；And the American Ginseng property of medicine belongs to cool property, with nourishing lung yin, yin-nourishing life rule, clearind deficient heat the effect of, be considered as mend and not It is dry, so being more suitable for the symptoms such as insomnia, irritated, memory loss and senile dementia.Ginsenoside includes panaxatriol and people Ginseng diol type saponin(e is considered as the primary pharmacological activity composition of ginseng and American Ginseng Central nervous systemic effect.Ginseng is more western American ginseng contains more panaxatriol type saponin(es, and American Ginseng then contains more diol type saponin(es.There are some researches prove, ginseng can promote Enter that central excitatory is moved while still alive and American Ginseng has a maincenter sedation, this drug effect difference is mainly by their contained ginseng soaps The difference of glycosides is determined.

It can be seen that, PDS and saponin triol are closely related with the property of medicine and drug effect, it should be used respectively；Otherwise The two mixes application, and when the central excitatory drug effect of triol saponins is needed, the maincenter of glycol saponins is calm to be made It is vice versa with the central excitatory drug effect that will weaken or offset triol saponins.But, ginseng and American Ginseng for a long time Mainly directly it is used as medicine with rhizome；And the health medicine or product of the extract of ginseng and American Ginseng is mainly general ginsenoside and includes Glycol and saponin triol.This be difficult to realize ginseng or American Ginseng or their total saposins product effectively treatment central excitatory or The medical value of inhibition disease and symptom.

The content of the invention

It is an object of the invention to provide a kind of application of PDS component in antipsychotic drug is prepared, The toxic and side effects such as the extrapyramidal symptoms caused including treatment schizophrenia and to antipsychotic drug；The medicine is PDS component is active component individually or together with other medicines such as chlorpromazine, haloperole or Clozapine, with medicine The medicine of acceptable carrier composition on.

The active component of the PDS component is ginsenoside Rb₁、Rb₂、Rb₃, Rc and Rd, this five kinds of ginsengs Diol saponin.PDS structural formula is as follows.

The PDS component that the present invention is used is prepared with reference to the method for CN2012102429281 embodiments 1, people Ginseng diol saponin constituent content 70-90%.PDS and existing anti-schizophrenia medicine（Such as Clozapine）Share, can increase The curative effect of strong existing antipsychotic drug simultaneously reduces the common toxic and side effect of existing anti-schizophrenia medicine（Such as extrapyramidal system is anti- Should）And improve the negative symptoms of schizophrenia（Such as cognition dysfunction）.

Included with pharmaceutical preparation made by PDS component:Oral formulations, injection, sustained release agent, controlled release agent, targeting Preparation or effervescent agent, oral formulations include oral tablet, lozenge, chewable tablets, pill, dripping pill, capsule, soft capsule, particle, oral Liquid, syrup, emulsion, mixture；Injection includes small-volume injection, big injection, powder-injection, emulsion, suspension.

The present invention is contained to PDS and saponin triol in the side reaction drug effect for reducing anti-schizophrenia medicine The research of difference, it was demonstrated that PDS component（Rb）The cognitive ability of schizophrenia animal pattern can be improved and can be resisted The neural toxic and side effect of various schizophrenia drugs；And Panaxatriol saponin（Rg）Then cause without mitigation schizophrenia drug Neural toxic and side effect, conversely, can also offset when sharing with PDS PDS antagonism schizophrenia medicine The toxic and side effect of thing.This just supports medical usage of the PDS in terms for the treatment of schizophrenia.

Specific embodiment

In conjunction with specific embodiments the invention will be further described for the present invention.But, the invention is not restricted to these embodiments.

Embodiment one prepares PDS component from ginseng roots medicinal material

The PDS component of the present invention separation of embodiment 1 in application number 201210242928.1 and pure It is prepared by change method.Ginseng or American Ginseng rhizome or base of leaf are ground into after meal with 50% ethanol water seepage pressure effects to extraction Liquid is colourless, merges after percolate decompression recycling ethanol and freeze-dried medicinal extract.Medicinal extract is dissolved in into 45% ethanol water In, sample liquid is separated with macroporous adsorbent resin column chromatography, is first eluted with 45% ethanol water anti-without obvious saponin(e to eluent Should, then eluted to eluent with 70% ethanol water and reacted without obvious saponin(e.By 70% ethanol eluate decompression recycling ethanol Afterwards and freeze-dried general ginsenoside (236.8 grams).General ginsenoside is dissolved in 50% ethanol water, sample liquid Octadecylsilane chemically bonded silica column chromatography for separation is used, is first eluted with 50% ethanol water anti-without obvious saponin(e to eluent Should, eluted with 75% ethanol water afterwards.Divide the ethanol eluate of Fraction collection 75%, with ginseng soap in HPLC methods detection each component Glycosides Rb₁、Rc、Rb₂、Rb₃With the content of Rd, will be containing ginsenoside Rb₁、Rc、Rb₂、Rb₃Merge with each component of Rd, amalgamation liquid After decompression recycling ethanol and freeze-dried PDS component.

The impact of the PDS component of embodiment two and Panaxatriol saponin to the nervimotion toxicity of haloperole

1. the nervimotion toxic and side effect that PDS antagonism haloperole causes

PDS component is observed by pole-jump test（Rb）To haloperole（HAL）Nervimotion toxic action Reduction effect.

The male ICR adult mices of environment 6-7 days, 30 ± 5g of body weight will be adapted in laboratory, fluorine piperazine will be uniformly divided at random Pyridine alcohol（2.0mg/kg, lumbar injection ip）Group, PDS（Abbreviation Rb, 40mg/kg, ip）With haloperole（2.0mg/ kg）Share（Abbreviation Rb40+HAL）Group, PDS（Abbreviation Rb, 60mg/kg, ip）With haloperole（2.0mg/kg）Close With（Abbreviation Rb60+HAL）Group and PDS（Abbreviation Rb, 80mg/kg, ip）With haloperole（2.0mg/kg）Share （Abbreviation Rb40+HAL）Group, per group of 8 animals.Rb intraperitoneal administrations（ip）In haloperole intraperitoneal administration（ip）Front 45min is carried out, Haloperole administration before 45min and be administered after 45min, the use of the method for neurotoxicity and cognitive function toxicity test is pole-climbing The sports coordination ability and cognitive function of experimental observation each group animal, fluorine piperazine is judged by the reduction of the animal movement coordination ability Protective effect of the kinesitherapy nerve toxicity and PDS component that pyridine alcohol is produced to this toxicity.

Pole-jump test determines neurovirulent condition：Experimental provision is the wooden stick with a length of 50cm of wooden base, and upper end is The little wooden shot of diameter 3cm, wooden stick is with base into 90 degree.Experimental procedure：By experiment mice head, upwards vertical four limbs are placed on little wood entirely On ball, record mouse head is rotated to be the head downward time from above（Tturn）And climb completely to the time on ground（Ttotal）, it is whole Individual experimental period is 90s, and if above action is not completed in 90s 90s is considered as.4 days mouse need to enter daily before experiment starts The row training stage, to guarantee that pole-climbing can be completed, is carried out according to the method described above during formal experiment.

Result of study（Table 1）Show, PDS component can reduce the neurotoxicity of haloperole.Can from table 1 See, haloperole lumbar injection (ip, 2mg/kg) afterwards 45min with administration before have significant difference (^{＆ ＆ ＆}P<0.001), mould is illustrated Type is successfully established;Each group before administration numerical value closely, difference that there are no significant, illustrate be administered after data be relatively feasible 's；The Tturn and Ttotal of HAL+Rb60 groups and HAL+Rb80 groups is significantly lower than HAL groups (* * P<0.01).As can be seen here, Rb can HAL kinesitherapy nerve toxicity is significantly decreased, and Rb60mg/kg is dose,optimum.So in ensuing experiment panoxadiol soap Glycosides is using the dosage of 60mg/kg.

The reduction unprotect effect of the sports coordination ability that Panaxatriol saponin's component is induced haloperole, weakens on the contrary The protective effect of PDS

This example probes into the secondary work of nervimotion poison that Panaxatriol saponin's component causes to haloperole by pole-jump test There is attenuation with whether, and determine whether Panaxatriol saponin's component can share with PDS component.

The male ICR adult mices of environment 6-7 days, 30 ± 5g of body weight will be adapted in laboratory, HAL will be uniformly divided at random （2.0mg/kg, ip）Group, HAL+Rb60 (60mg/kg, ip) group, HAL+ Panaxatriol saponin's components（Abbreviation Rg, 30mg/kg, ip）Group, HAL+Rg (60mg/kg, ip) group, HAL+Rb30+Rg30 groups, HAL+Rb60+Rg60 groups, per group of 8 animals.Rb and Rg 45min carries out intraperitoneal injection before HAL administrations（ip）, and using example one（1）In Behaviors survey（Pole-climbing is tried Test）It is observed（Assay method is ibid）.

As seen from Table 2, to piperidine alcohols（HAL）Before, each group mouse head is rotated to be the downward time from above（Tturn）And Climb completely to the time on ground（Ttotal）There was no significant difference, illustrates that each group animal is homogeneous before administration；To HAL 45 After min, HAL model group mouse heads are rotated to be the downward time from above（Tturn）And climb completely to the time on ground （Ttotal）Before being considerably longer than to HAL (^{＆ ＆ ＆}P<0.001), illustrate that HAL causes obvious nervimotion toxic and side effect.Rb groups Or Rg groups compare with HAL groups, Tturn the and Ttotal times of HAL+Rb60 groups significantly shorten (* * * P<0.001), ginseng is illustrated Diol saponin（Rb）The alcohol-induced nervimotion toxicity of piperidines can be resisted；And HAL+Rg30 groups and HAL+Rg60 compare with HAL groups, There are the trend of prolongation their Tturn and Ttotal times, illustrate Panaxatriol saponin（Rg）The toxicity of HAL is made without reduction With contrary possible aggravation chlorpromazine neurotoxicity；HAL+Rb30+Rg30 groups and HAL+Rb60+Rg60 groups and HAL+Rb60 group phases Than their Ttotal and Tturn times significantly extend（^##P<0.01）, illustrate that Panaxatriol saponin can weaken panoxadiol The nervimotion toxic and side effect that saponin(e antagonism piperidine alcohols cause.It follows that including piperidine alcohols schizophrenia drug is reduced Neurovirulent medical usage aspect, PDS component and Panaxatriol saponin's component are carried out separating be necessity 's.In related experiment afterwards, the main effect for determining PDS component of the present invention.

Embodiment three

1. the dosage of the nervimotion attenuation that PDS component causes to chlorpromazine is groped

The suitable dose that chlorpromazine causes nervimotion toxicity is first groped by the grip experiment of mouse, this dosage is then used Determine the impact of the nervimotion toxicity that PDS component causes to chlorpromazine.

The male ICR adult mices of environment 6-7 days, 30 ± 5g of body weight will be adapted in laboratory, chlorine third will be uniformly divided at random The mg/kg of piperazine 4,6,8（Lumbar injection, ip）Three concentration gradient groups, to seek suitable dosage, per group of 3 mouse. The device of grip measuring myasthenia toxicity is the big mouse grip analyzer of YLS-13A types.Condition determination：Every mouse is parallel Determine 3 times, per minor tick 5min；Data processing：Grip is reduced（%）=［ grip (g) after the grip (g) before administration-administration ］/ Grip (g) × 100% before administration, the myasthenia state that grip reduces mouse after bigger explanation is processed is more obvious.As shown in Table 3, In dosage gropes experiment there is obvious significant difference in CHL6 groups with CHL4 groups（**P<0.01）, CHL8 groups deposit with CHL4 groups In significant difference；There was no significant difference with CHL8 groups for CHL6 groups.It follows that CHL is most suitable test dose in 6mg/kg.

From table 3, in this experiment the grip of CHL6 groups and CHL8 groups is reduced substantially than being more than CHL4 groups, and is existed aobvious Write sex differernce（*P<0.05, * * P<0.01）, while the standard deviation that CHL6 group animals grip is reduced is less, it is more suitable for model With related experiment later.

The attenuation of the nervimotion toxicity that PDS component causes to chlorpromazine

Seek whether PDS component has what neurotoxicity was reduced to chlorpromazine by the grip experiment of mouse Effect.

The male ICR adult mices of environment 6-7 days, 30 ± 2g of body weight, random uniformly point chlorpromazine are adapted in laboratory 6mg/kg（Lumbar injection, ip）Group, Rb60+CHL6 groups, per group of 8 animals.Rb is administered front 45 min and carries out lumbar injection in CHL Administration, chlorpromazine（CHL）Group gives equal-volume physiological saline.45min is determined respectively after Rb is administered front 45 min and CHL administrations The forelimb grip of animal, statistical analysis each group is to the change before and after CHL.

In example two（1）On the basis of, further determine PDS component（Rb）The nerve fortune that chlorpromazine is caused The impact of dynamic toxicity.Experiment packet includes chlorpromazine（CHL, 6 mg/kg, ip）Group and mg/kg (ip) groups of Rb 60, per group 8 Animal, Rb 45 min before to CHL carry out intraperitoneal injection, and CHL groups give isopyknic physiological saline.To Rb or life 45 min after 45 min and medicine CHL, determine animal forelimb grip before reason salt solution.

From table 4, CHL6 groups reduce by 42% in the 45 min right fores grips to the mg/kg of CHL 6, and panoxadiol Saponin(e（Rb60+CHL6）Prevention group reduces by 21%, there is the difference of highly significant between two groups（**P<0.01）, illustrate panoxadiol Saponin(e has obvious inhibitory action to the neuromuscular toxicity that chlorpromazine causes.This result of study supports panoxadiol soap Glycosides reduces the neurovirulent clinical practice of schizophrenia drug.

The attenuation of the nervimotion toxic and side effect that example IV PDS component is induced Clozapine

By mouse muscle it is stiff experiment be used as index determine PDS Clozapine is caused nervimotion poison The abated effect of property.

The male ICR adult mices of environment 6-7 days, 30 ± 5g of body weight will be adapted in laboratory, chlorine nitrogen will be uniformly divided at random It is flat（CLO 20、30mg/kg,ig）Two groups and PDS joint Clozapine（Rb60+CLO20、Rb40+CLO30） Individual group, totally 6 groups, per group of 8 animals.In drug combination group, Rb is administered prior to Clozapine 45min, CLO various dose group animals Equal-volume physiological saline is given, 30min is measured before Rb administrations and after Clozapine administration for muscular rigidity experiment.

Muscular rigidity experimental provision：It is fixed on horizontal plane, high 50 millimeters, wide 3 millimeters of wood chip.Experiment condition and method： Mouse forelimb is positioned over into wood chip upper end, the time that mouse forelimb keeps stiff is recorded, experimental period is 30s, if more than 30s It is considered as 30s.Dead time (T1, S) before dead time (T2, S)-experiment after stiff time (S)=administration 30min, difference is got over Big explanation stiffness is more serious, i.e. the kinesitherapy nerve toxicity of Clozapine is stronger.

From the experimental result of table 5, to Clozapine（CLO 20 or 30, mg/kg）30 min afterwards, the dead time of animal shows Write and extend（^&&&P<0.001）, illustrate that CLO causes the toxic and side effect of muscular rigidity；CLO20+Rb60 groups and CLO30+Rb60 groups Compared with respective CLO control groups, its dead time significantly reduces（^*P<0.05）.Thus illustrate, PDS is in agent Measure for 60mg/kg when be that the kinesitherapy nerve toxicity of Clozapine of 20,30mg/kg has obvious inhibitory action to dosage, this is just Support.

Improvement result of the PDS of embodiment five to the cognition dysfunction of mouse schizophrenia model

This experiment recognizes measuring PDS component in mouse schizophrenia model by nouveaut Improvement result to cognition dysfunction.

The male ICR adult mices of environment 6-7 days, 30 ± 5g of body weight are adapted in laboratory, using biphenyl Horizon（MK 801）Carry out intraperitoneal administration to cause schizophrenia model within continuous 6 days.It is that the MK801 for eliminating remaining in vivo makes after last dose Into experimental error, carry out the wash-out phase of three days.After the wash-out phase, open field experiment is carried out（open field）And with its knot Fruit is uniformly divided into Normal group, MK801 models, Rb40 (40 mg/kg), Rb60 (60 mg/kg), and arranging according to group is carried out Administration 7 days；Concurrently set Normal group.After last dose 1h, nouveaut experiment is carried out.

Open field test principle：Spacious field is tested（Open field test) it is evaluation experimental animal new also known as Open field test A kind of method of independent behaviour, exploratory behavior and tensity in different environment.Some behaviors among novel environment with animal used as test Occurrence frequency and duration etc. be index, independent behaviour and exploratory behavior of the reaction experiment animal in foreign environment.Dress Put：Self-control specification is 150*150*40 without bottom surface box, and ground can be replaced by ground, and the pros of 10*10 are drawn on the ground Shape 25（5*5）It is individual.Condition and parameter：Room temperature；Artificial light；Total move distance.Step：1h removes mouse to experiment before a, experiment Room, with adapting to surrounding environment b, toy behavior analysis system by spacious field experimental provision from the beginning of upper left, by left-to-right In different colors numbering is 25 little lattice of identical to order, wherein 7,8,9,12,13,14 and 19 is middle section, remaining is outer Zhou Ge, No. 13 lattice pinch mousetail and are put in center lattice when testing every time for center lattice, observe its active situation, determine every time Terminate to remove animal excrements it is clean, and with 70% alcohol wipe device, per only only determining 1 time, each 5min.

Nouveaut experimental provision：The box of the square of 50*50*50；Condition and parameter：Carry out under room temperature condition； Go to smell near the centimeters nose of new object 1 and touch or nose touches time (Tn) of new object, similarly record in standard Time at thing（Tf）.Step：A, front 24h is being tested or trained, animal is being placed in the room of test, adaptive testing ring Border.B, experiment are divided into two stages, the interval 1h in two stages.First stage is that two are placed in laundering period, device completely Identical object, is put into the midpoint of two objects in device so as to adapt to 3min by mouse；Second stage is experimental stage, One of object is changed into the object differed with it and repeats above step.Formula：Contact the ratio=(Tn- of new object time Tf)/(Tn+Tf)。

Result of study（Table 6）Show, the new object time scale of contact of MK801 model groups is significantly lower than Normal group（^& P<0.05）, show that MK801 model groups are reduced to the interest of new things, indicate modeling success;Rb40 groups are new with the contact of Rb60 groups Object time scale is apparently higher than MK801 model groups（^*P<0.05, * * P<0.01）, and Normal group is near and above respectively. As can be seen here, Rb has significant improvement result to the cognition dysfunction that schizophrenia model is caused, and can return to normal Level is even better than normal level.This just further supports PDS can improve the cognitive barrier of schizophreniac The clinical application for hindering.

Claims (3)

1. application of the PDS active component in antipsychotic drug is prepared, the PDS component Mainly include ginsenoside Rb₁、Rb₂、Rb₃, five kinds of PDSs of Rc and Rd, their structural formula is：

Characterized in that, what the medicine was allowed by PDS component and other treatment schizophrenia drugs and preparation Excipient or carrier are made, and described other treatment schizophrenia drugs select chlorpromazine, haloperole or Clozapine.

2. application according to claim 1, it is characterised in that the dosage form of the medicine is liquid preparation, solid system Agent.

3. application according to claim 1, it is characterised in that the administering mode of the medicine is for oral administration or is administered to Medicine or oral nasal spray to medicine.